Video Experimental Relacionado
Updated: Jul 17, 2026
09:12
MISSION LentiPlex Pooled shRNA Library Screening in Mammalian Cells
Published on: December 21, 2011
Una prueba genética identifica a PITX1 como un supresor de la actividad RAS y de la tumorigenicidad
Ingrid G M Kolfschoten1, Bart van Leeuwen, Katrien Berns
1Division of Tumor Biology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
Cell
|June 18, 2005
Resumen
PITX1 actúa como un supresor de tumores mediante la inhibición de la vía RAS. La baja expresión de PITX1 se correlaciona con el cáncer, y su restauración reduce el crecimiento tumoral, revelando un nuevo mecanismo en el desarrollo del cáncer.
Área de la Ciencia:
- Oncología Oncología.
- Biología Molecular Biología Molecular
- Genética La genética.
Sus antecedentes:
- La activación de las mutaciones RAS impulsa la tumorigénesis, pero muchos cánceres tienen RAS de tipo salvaje, lo que sugiere mecanismos de activación alternativos.
- La identificación de nuevos genes supresores de tumores es crucial para comprender el desarrollo del cáncer y encontrar nuevos objetivos terapéuticos.
Objetivo del estudio:
- Identificar nuevos genes supresores de tumores involucrados en el desarrollo del cáncer.
- Para investigar el papel de PITX1 en la regulación de la vía RAS y la tumorigénesis.
Principales métodos:
- Examinó una biblioteca de interferencia de ARN en busca de genes cuya eliminación transforma las células primarias humanas sin RAS oncogénico.
- Se evaluó la expresión de PITX1 en tumores humanos y líneas celulares de cáncer.
- Restauró la expresión de PITX1 en células de cáncer de colon y evaluó su efecto sobre la tumorigenicidad.
- Identificó RASAL1 como un objetivo de transcripción de PITX1.
Principales resultados:
- Identificó PITX1 como un nuevo gen supresor de tumores.
- La eliminación de PITX1 activa la vía RAS y promueve la tumorigenicidad.
- Se observó una baja expresión de PITX1 en tumores de próstata, vejiga y líneas celulares de cáncer de colon RAS de tipo salvaje.
- La restauración de PITX1 inhibió la tumorigenicidad de una manera dependiente del RAS de tipo salvaje.
- PITX1 regula a la baja la vía RAS a través de la regulación transcripcional de RASAL1.
Conclusiones:
- PITX1 funciona como un supresor tumoral mediante la regulación a la baja de la vía RAS a través de RASAL1.1.
- La desregulación del eje PITX1-RASAL1 puede contribuir a la tumorigénesis en cánceres con tipo salvaje RAS.
Videos de Conceptos Relacionados
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
02:38The Ras Gene
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Ras is a superfamily...
01:20The Retinoblastoma Gene
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
02:38The Ras Gene
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Ras is a superfamily...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...